Dáil Éireann Debate, Thursday - 19 March 2026
513. Deputy John Clendennen asked the Minister for Health for an update on the accessibility of Belzutifan (brand name Welireg) for the treatment of Von Hippel-Lindau syndrome; and if she will make a statement on the matter. [21311/26]
Amharc ar fhreagraUnder the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
